Built on Atlas AI™, Ask Atlas allows care teams to ask plain-language questions across their own clinical, operational, and billing data, returning structured answers in seconds. HOUSTON, May 26, 2026 /PRNewswire/ -- Octagos today announced the launch of Ask Atlas, a new AI intelligence capability allowing cardiac device clinics to query their own remote monitoring data using natural language. Continue Reading Ask Atlas™ by Octagos Speed Speed Built on Atlas AI, the intelligence layer of the Oc

Cambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly launched company established by Human Longevity, Inc. today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science. As aging populations reshape global labor markets a

Collaborative research explores how breakthrough engineered therapy works, why remission lasts for some patients, and how to extend its benefits NEW YORK, May 26, 2026 /PRNewswire/ -- Today, the Lupus Research Alliance (LRA), the world's largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT). The new program aims to d

SAN DIEGO, May 26, 2026 /PRNewswire/ -- The Deerborne Group, a specialized strategy and management consulting firm focused exclusively on the genomics and precision diagnostics industry, today announced that senior leadership will attend the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago, Illinois. ASCO 2026 comes at a pivotal time for the oncology diagnostics industry as companies navigate increasing pressure to align scientific innovatio

NEW YORK, May 26, 2026 /PRNewswire/ -- To accelerate Parkinson's disease (PD) research and connect eligible participants with clinical trials, the Parkinson's Foundation announced the first major milestone of its new PD Trial Navigator pilot program. Aiming to advance the process of matching people living with PD with relevant studies, the PD Trial Navigator initiative identified more than 2,000 potential participants for screening into the NEULARK trial, sponsored by Neuron23 . "The launch

Despite growing awareness and demand, access to FDA-approved obesity medications remains out of reach for many people affected by the disease of obesity. TAMPA, Fla., May 26, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is highlighting findings from a new national analysis of U.S. health insurance coverage that reveals a significant gap between reported coverage of obesity medications and actual patient access to care. The findings suggest that traditional measures of coverage may ove

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company’s quality control process. Sensors identified

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients MUMBAI, India and PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies,

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care

VIENNA, May 26, 2026 /PRNewswire/ -- A new episode of Beyond Biotech podcast, produced by Labiotech, is now live, featuring Dr. Stéphane Barges, CEO of Lexogen, alongside Dr. Quin Wills, Founder and CEO of Ochre Bio. In this episode, Lexogen's CEO shares his perspective on the growing role of RNA sequencing and transcriptomics in enabling AI-driven drug discovery. The discussion highlights how high-quality, dedicated data built with AI training in mind is becoming essential to improve relevant t